Previous 10 | Next 10 |
AtriCure (NASDAQ: ATRC ): Q1 Non-GAAP EPS of -$0.36 beats by $0.04 ; GAAP EPS of -$0.42 misses by $0.01 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Worldwide revenue of $53.2 million – a decrease of 1.4% year over year U.S. revenue of $43.5 million – an increase of 1.1% year over year International revenue of $9.8 million – a decrease of 11.0% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a l...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences. AtriCure will be participating in the Bank ...
The stock market's tumble in mid-March was driven by indiscriminate selling caused by an awakening to the possibility of double-digit unemployment and up to a 30% drop in second quarter gross domestic product ((GDP)), coupled with changes in margin requirements resulting in forced liquidation....
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020. AtriCure will host a conference call ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhyt...
Citing COVID-19 disruptions, AtriCure (NASDAQ: ATRC ) is withdrawing its previously issued financial guidance for 2020. More news on: AtriCure, Inc., Healthcare stocks news, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic. “Throu...
AtriCure, Inc. (ATRC) Q4 2019 Results Earnings Conference Call February 18, 2020 04:30 PM ET Company Participants Lynn Lewis - Gilmartin Group, Investor Relations Mike Carrel - President and Chief Executive Officer Andy Wade - Chief Financial Officer Conference Call Participan...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q4 2019 Earnings Call Feb 18, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...